

# Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date January 22, 2010

Frontier Building, 3601 C Street; Room 890/896

## REVISED Agenda

Call in: 1-800-315-6338. Use access code 735#.

**DRAFT**

Call to Order – Chair Richard Brodsky, MD

8:00 am

Roll Call

8:05 am

Public Comment - (See guidelines on page 2)

Local Public / Health Practitioners

The Department has developed a new method for class review to better utilize the time of the P&T Committee. Three sets of classes are up for review. Classes shown in **Red** are new classes or classes where new information exists and public testimony will be taken. Classes shown in **Blue** will be reviewed only if new information is received, then public testimony will be taken. For the classes shown in **Green**, no changes have been noted and no public testimony will be taken. New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.

Public Comment on Blue/Red Classes	
Discussion & vote on <b>Red Classes</b>	
The Department will review the following <b>red classes</b> as the classes are new or new information exists.	
<b>Re-Review Benzoyl Peroxide / Clindamycin Combos</b>	<b>Re-Review Topical Retinoids</b>
<b>*Review Topical Anesthetics</b>	<b>*Review Topical NSAIDS</b>
<b>Re-Review Incretin Mimetics</b>	
The Department proposes no changes to the P&T Committee's clinical recommendation in the following <b>blue classes</b> unless new information is received.	
<b>Re-Review Ulcerative Colitis – Oral</b>	<b>Re-Review ARB's</b>
<b>Re-Review Oral Beta Blockers</b>	<b>Re-Review Insulins</b>
<b>Re-Review TZD's</b>	
The Department proposes no changes to the P&T Committee's clinical recommendation to the following classes as shown in <b>green</b> .	
<b>Re-Review Sulfonylureas</b>	<b>Re-Review Biguanides</b>
<b>Re-Review Meglitinides</b>	<b>Re-Review Ace Inhibitors</b>
<b>Re-Review Alpha Glucosidase Inhibitor</b>	<b>Re-Review Renin Inhibitors</b>
<b>Re-Review CCB's</b>	<b>Re-Review Immunosuppressants</b>
<b>Re-Review Glaucoma Agents</b>	<b>Re-Review Topical Immunomodulators</b>
Break as needed – 15 minutes -	
Review minutes from November 2009 meeting	
Comments from Committee Members or Chair	
Adjourn	

**GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE**  
**January 22, 2010**

1. All interested speakers are required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area, prior to the start of the meeting.
2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of three (3) minutes in total.
3. Only one speaker "slot" will be available per drug class representing a single manufacturer or interest group. Within the allowable three (3) minute time period, multiple speakers may share this "slot".
4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
6. Written medical information is not accepted at the P&T meeting. This is to be submitted First Health prior to the meeting.